Search

Displaying results 5811 - 5820 of 10000 in total
  1. Drug

    Bardoxolone methyl

    go.drugbank.com/drugs/DB05983
    Investigational

  2. Drug

    INCB7839

    go.drugbank.com/drugs/DB05033
    Investigational

    INCB7839 is a novel, orally available ADAM metalloprotease inhibitor that is designed to block activation of the epidermal growth factor (EGFR) pathways. … It represents a potentially important new class of targeted breast cancer therapy. It has shown promising clinical activity in heavily pretreated, refractory breast cancer patients.

  3. Drug

    Aranidipine

    go.drugbank.com/drugs/DB09229
    Experimental

    It is a calcium antagonist with the formula methyl 2-oxopropyl 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylate. … Aranidipine is a novel dihydropyridine derivative that gives rise to two active metabolites (M-1α and M-1β) that exhibit hypotensive activity.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  4. Drug

    BNC105

    go.drugbank.com/drugs/DB06313
    Investigational

  5. Drug

    Tezacitabine

    go.drugbank.com/drugs/DB06433
    Investigational

    A synthetic purine nucleoside analogue with potential antineoplastic activity.

  6. Drug

    CR002

    go.drugbank.com/drugs/DB05139
    Investigational

    CR002 is a novel investigational fully human monoclonal antibody that blocks the activity of excess platelet-derived growth factor-D (PDGF-D), a target shown to play a role in kidney inflammation. … This is a novel therapeutic approach to treat kidney inflammation.

  7. Drug

    beta-Hydroxybutyric acid

    go.drugbank.com/drugs/DB16506
    Investigational

    Beta-hydroxybutyrate is being studied in around 230 clinical trials, including NCT06351124 (recruiting for Crohn's disease), NCT05584371 (recruiting for safety and tolerability of exogenous ketosis), NCT04656236 (completed for type 1 dia...

  8. Drug

    TD-2749

    go.drugbank.com/drugs/DB05905
    Experimental

    such as chronic constipation, constipation-predominant irritable bowel syndrome (C-IBS), opioid-induced constipation, functional dyspepsia and diabetic gastroparesis. … TD-2749 is selective 5-HT4 agonists discovered by Theravance through the application of multivalent drug design in a drug discovery program dedicated to finding new medicines for GI motility disorders

  9. Drug

    OBE101

    go.drugbank.com/drugs/DB05080
    Experimental

    OBE101 is a new weight loss drug developed by Obecure Ltd. It is a new formulation that is based on the vertigo medication, Betahistine. … Obecure is repurposing betahistine, which is an H1 receptor agonist and partial H3 receptor antagonist for the treatment of obese individuals and for other weight management indications.

  10. Drug

    Androstenediol

    go.drugbank.com/drugs/DB01524
    ExperimentalIllicit

    Androstenediol is an intermediate in [testosterone] biosynthesis, found in the testis or the adrenal glands. … Androstenediol, derived from dehydroepiandrosterone by the reduction of the 17-keto group (17-hydroxysteroid dehydrogenases), is converted to testosterone by the oxidation of the 3-beta hydroxyl group to a